Search Result

Pathways Recommended:	JAK/STAT Signaling

Results for "

A jak Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (233) Acyltransferase (1) Akt (2) Antibiotic (4) Apoptosis (51) Arginase (1) Aurora Kinase (3) Autophagy (20) Bacterial (7) Bcr-Abl (4) BMX Kinase (1) Btk (11) CDK (7) COX (2) Cytochrome P450 (1) Deubiquitinase (2) Dopamine Receptor (1) Drug Metabolite (2) EGFR (8) Endogenous Metabolite (3) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (2) FGFR (1) FLT3 (17) Fungal (6) GSK-3 (4) HDAC (4) IFNAR (2) IKK (4) Influenza Virus (2) Interleukin Related (6) Isotope-Labeled Compounds (6) Itk (1) JNK (2) Keap1-Nrf2 (4) LRRK2 (1) MEK (2) MicroRNA (1) Microtubule/Tubulin (1) Mitophagy (6) mTOR (1) nAChR (1) NF-κB (3) NO Synthase (1) Orthopoxvirus (1) Oxidative Phosphorylation (1) p38 MAPK (3) Parasite (1) PI3K (1) PKC (1) Polo-like Kinase (PLK) (2) PROTACs (4) Reactive Oxygen Species (1) RET (3) RIP kinase (1) Sirtuin (4) Src (2) STAT (30) STING (1) Syk (8) TGF-β Receptor (2) TNF Receptor (1) Trk Receptor (1) Tyrosinase (1) VEGFR (3) Virus Protease (1)
By Research Areas:	Cancer (167) Cardiovascular Disease (3) Infection (9) Inflammation/Immunology (122) Metabolic Disease (2) Neurological Disease (5)
Click Chemistry:	Alkynes (3)

279

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-100759

JAK2-IN-4

JAK Cancer

JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .

JAK2-IN-4	JAK	Cancer
JAK2-IN-4 (compound 16h) is a selective *JAK2/JAK3* inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .

HY-161139

JAK1-IN-14	JAK	Inflammation/Immunology
JAK1-IN-14 (Compound 12a) is a potent and selective *JAK1* inhibitor. JAK1-IN-14 inhibits *JAK1* and *JAK2* with an IC₅₀ value of 12.6 nM and 135 nM. JAK1-IN-14 suppresses hepatic fibrosis levels and can be used for the research of liver fibrosis and inflammatory diseases .

HY-156535

JAK kinase-IN-1	JAK	Inflammation/Immunology
JAK kinase-IN-1 (Example 1) is a *JAK* inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC₅₀ values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively .

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .

HY-15480

NSC 42834 1 Publications Verification jak2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits* Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-116505

JAK1-IN-4	JAK	Cancer
JAK1-IN-4 is a potent and selective *JAK1* inhibitor, with IC₅₀s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC₅₀, 227 nM) .

HY-151285

JAK-2/3-IN-3	Apoptosis JAK	Inflammation/Immunology Cancer
JAK-2-/3-IN-3 (compound ST4j) is a potent *JAK2/3* inhibitor with IC₅₀s of 13.00 and 14.86 nM for *JAK2* and *JAK3, respectively. JAK-2-/3-IN-3 inhibits* autophosphorylation of *JAK2* and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia .

HY-147975

JAK3-IN-12	JAK	Inflammation/Immunology
JAK3-IN-12 (compound 5k) is a highly potent *JAK3* inhibitor with IC₅₀ values of 9.5 nM, 18 nM and 42 nM for JAK3, JAK1 and JAK2, respectively. JAK3-IN-12 can be used for researching rheumatoid arthritis .

HY-144440

JAK1-IN-9

JAK Cancer

JAK1-IN-9 (compound 23a) is a potent and selective JAK1 inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more .

JAK1-IN-9	JAK	Cancer
JAK1-IN-9 (compound 23a) is a potent and selective *JAK1* inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more .

HY-137756

JAK2-IN-6	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .

HY-10652

JAK-2/3-IN-1	JAK	Inflammation/Immunology Cancer
JAK-2/3-IN-1 is a potent *JAK-2* and *JAK-3* inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms .

HY-111750

JAK-IN-3

JAK Inflammation/Immunology

JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC₅₀ values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively .

JAK-IN-3	JAK	Inflammation/Immunology
JAK-IN-3 (compound 22) is a potent *JAK* inhibitor, with IC₅₀ values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively .

HY-146727

JAK3-IN-11	JAK	Inflammation/Immunology
JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active *JAK3* inhibitor with IC₅₀ value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T cell proliferation, is a promising tool for study autoimmune diseases .

HY-19544

JAK3-IN-1	JAK	Cancer
JAK3-IN-1 is a potent, selective and orally active *JAK3* inhibitor with an IC₅₀ of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for *JAK3* than JAK1 (IC₅₀ of 896 nM) and JAK2 (IC₅₀ of 1050 nM) .

HY-13827

JAK-IN-1 1 Publications Verification	JAK	Inflammation/Immunology
JAK-IN-1 is a *JAK1/2/3* inhibitor with IC₅₀s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.

HY-133747

JAK3-IN-9	JAK	Inflammation/Immunology
JAK3-IN-9 is an orally active *JAK3* inhibitor with IC₅₀ value of 1.7 nM. JAK3-IN-9 is highly selective to the *JAK3* signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows good anti-arthritis activity. JAK3-IN-9 can be used in autoimmune disease research .

HY-13961

GLPG0634 analog

JAK Cancer

GLPG0634 analog (Compoun 176) is a broad spectrum JAK inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3 .

GLPG0634 analog	JAK	Cancer
GLPG0634 analog (Compoun 176) is a broad spectrum *JAK* inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3 .

HY-10963

Momelotinib Mesylate CYT387 Mesylate	JAK Autophagy	Cancer
Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.

HY-153440

JAK-IN-25	JAK	Cancer
JAK-IN-25 (compound 19) is a potent *JAK* inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research .

HY-139807

JAK-IN-14	JAK	Inflammation/Immunology
JAK-IN-14 is a potent and selective *JAK1* inhibitor, with an IC₅₀ of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16) .

HY-10961

Momelotinib 10+ Cited Publications CYT387	JAK Autophagy Apoptosis	Cancer
Momelotinib (CYT387) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.

HY-130247

JAK2/FLT3-IN-1 1 Publications Verification	JAK FLT3 Apoptosis	Cancer
JAK2/FLT3-IN-1 is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .

HY-143444

JAK-IN-20	JAK	Inflammation/Immunology
JAK-IN-20 is a potent, pan and orally active *JAK* inhibitor with an IC₅₀s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo .

HY-14435

Pyridone 6 5+ Cited Publications	JAK	Cancer
Pyridone 6 is a *pan-JAK* inhibitor, which potently inhibits the JAK kinase family, with IC₅₀s of 1 nM for *JAK2* and TYK2, 5 nM for *JAK3, and 15 nM for JAK1*, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

HY-15315A

Baricitinib phosphate 35+ Cited Publications LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2* inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-12469

Decernotinib 3 Publications Verification VX-509; VRT-831509	JAK	Inflammation/Immunology
Decernotinib is a potent, orally active *JAK3* inhibitor, with K_is of 2.5, 11, 13 and 11 nM for *JAK3, JAK1, JAK*2, and TYK2, respectively.

HY-154994

JAK-IN-30	JAK	Inflammation/Immunology
JAK-IN-30 (compound 31) is a water-soluble *JAK* inhibitor with IC₅₀ values of 2, 15, 18 and 2 nM for *JAK2, JAK1, JAK3* and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .

HY-130247A

JAK2/FLT3-IN-1 TFA 1 Publications Verification	JAK FLT3 Apoptosis	Cancer
JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity .

HY-149296

JAK1-IN-12	JAK	Inflammation/Immunology
JAK1-IN-12 is a selective inhibitor of *JAK1, with IC₅₀* of 0.0246 μM. And IC₅₀s of 0.423 μM, 0.410 μM and 1.12 μM for JAK2, JAK3 and TYK2. JAK1-IN-12 promotes hair growth in mice. JAK1-IN-12 can be used for research of immune and inflammatory diseases .

HY-18300

Filgotinib 15+ Cited Publications GLPG0634	JAK	Cancer
Filgotinib (GLPG0634) is a selective and orally active *JAK1* inhibitor with IC₅₀ of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-151256

JAK-2/3-IN-2

JAK Cancer

JAK-2/3-IN-2 (Compound 3h) is a JAK2 and JAK3 inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively .

JAK-2/3-IN-2	JAK	Cancer
JAK-2/3-IN-2 (Compound 3h) is a *JAK2* and *JAK3* inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively .

HY-161015

JAK1-IN-13	JAK	Inflammation/Immunology
JAK1-IN-13 (compound 36b) is an orally active, potent and highly selective inhibitor of *JAK1* with an IC₅₀ of 0.044 nM. JAK1-IN-13 significantly decreases STAT3 phosphorylation .

HY-162248

JAK1/2-IN-1	JAK Interleukin Related	Inflammation/Immunology Cancer
JAK1/2-IN-1 is a potent *JAK1* and *JAK2* inhibitor with IC₅₀ values of 0.4 nM and 8.1 nM, respectively. JAK1/2-IN-1 also inhibits IL-4 and IL-13 with IC₅₀s of 136.5 nM and 19.1 nM, respectively (WO2023244775A1; Example 33a) .

HY-149283

JAK/HDAC-IN-2	JAK HDAC Apoptosis	Cancer
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine *JAK/HDAC* dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers .

HY-10962

Momelotinib sulfate 10+ Cited Publications CYT387 sulfate salt	JAK Autophagy Apoptosis	Cancer
Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC₅₀=155 nM).

HY-145029

SYK/JAK-IN-1

Syk JAK Inflammation/Immunology Cancer

SYK/JAK-IN-1 is dual SYK/JAK inhibitor with IC₅₀s of <5 nM for SYK and JAK2, respectively .
HY-153712

JAK-IN-28

JAK Inflammation/Immunology Cancer

JAK-IN-28 (Compound 111) is a JAK inhibitor. JAK-IN-28 can be used for research of cancer or inflammatory diseases .

SYK/JAK-IN-1	Syk JAK	Inflammation/Immunology Cancer
SYK/JAK-IN-1 is dual *SYK/JAK* inhibitor with IC₅₀s of <5 nM for SYK and JAK2, respectively .

JAK-IN-28	JAK	Inflammation/Immunology Cancer
JAK-IN-28 (Compound 111) is a *JAK* inhibitor. JAK-IN-28 can be used for research of cancer or inflammatory diseases .

HY-155951

JAK3-IN-14	JAK	Cancer
JAK3-IN-14 (compound 1) is a potent *JAK3* inhibitor, with IC₅₀ values of 38 and 600 nM for *JAK3* and *JAK2, respectively. JAK3-IN-14 shows inhibitory of IL-4 and IL-3 induced TF-1 cell proliferation, with IC₅₀* values of 600 and 500 nM, respectively .

HY-163183

JAK3/BTK-IN-7	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-7 (XL-12) is a *JAK3/BTK* inhibitor with IC₅₀ values of 2 nM and 14 nM, respectively. JAK3/BTK-IN-7 has anti-inflammatory activity and can be used in the study of rheumatoid arthritis .

HY-154969

JAK-IN-29

JAK Others

JAK-IN-29 (compound 3) is a potent JAK inhibitor .
HY-157011

JAK-IN-33

JAK Inflammation/Immunology

JAK-IN-33 (compound 3 (R)) is a JAK inhibitor .

JAK-IN-29	JAK	Others
JAK-IN-29 (compound 3) is a potent JAK inhibitor .

JAK-IN-33	JAK	Inflammation/Immunology
JAK-IN-33 (compound 3 (R)) is a *JAK* inhibitor .

HY-143717

JAK3/BTK-IN-2	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-2 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)

HY-143720

JAK3/BTK-IN-5	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-5 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 35)

HY-143716

JAK3/BTK-IN-1	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-1 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002) .

HY-143718

JAK3/BTK-IN-3	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-3 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)

HY-143719

JAK3/BTK-IN-4	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-4 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)

HY-112724

Ivarmacitinib SHR0302	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly *JAK1. The selectivity of Ivarmacitinib for JAK1* is >10-fold for *JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits* *JAK1-STAT3* phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-112724A

Ivarmacitinib sulfate SHR0302 sulfate	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) sulfate is a potent and orally active all members of the JAK family inhibitor, particularly *JAK1. The selectivity of Ivarmacitinib for JAK1* is >10-fold for *JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits* *JAK1-STAT3* phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-101976

JAK3-IN-6

JAK Inflammation/Immunology

JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

423 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 423 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

HY-L016

Protein Tyrosine Kinase Compound Library

1055 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1055 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L017

Stem Cell Signaling Compound Library

1740 compounds

Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.

MCE owns a unique collection of 1740 compounds that can be used for stem cell regulatory and signaling pathway research.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1405

Cucurbitacin I 5+ Cited Publications Elatericin B; JSI-124; NSC-521777	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N1356

Reticuline	Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Disease Research Fields Lindera aggregata (Sims) Kosterm.	JAK STAT NF-κB Endogenous Metabolite
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects .

HY-N1447

Ganoderic acid A 4 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Polyporaceae Source classification Plants Endogenous metabolite Disease Research Fields Cancer	Apoptosis Autophagy Endogenous Metabolite
Ganoderic acid A can inhibit of the *JAK-STAT3* signaling pathway, also inhibit proliferation, viability, ROS.

HY-N2959

Brevilin A 3 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Euchresta horsfieldii (Lesch.) J. Benn. Plants Compositae Disease Research Fields Cancer	JAK STAT Apoptosis Autophagy
Brevilin A is an orally active *STAT3/JAK* inhibitor (STAT3 IC₅₀= 10.6 µM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy .

HY-N1405R

Cucurbitacin I (Standard) Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity .

HY-N3710

Dehydrocrenatidine Kumujian G; O-Methylpicrasidine I	Alkaloids Simaroubaceae Source classification Pyridine Alkaloids Plants	JAK Apoptosis
Dehydrocrenatidine, a natural alkaloid, is a specific *JAK* inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain .

HY-N2963

Broussonin E	Structural Classification Thymelaeaceae Source classification Daphne giraldii Nitsche Phenols Polyphenols Plants	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis .

HY-N12473

25-Deacetylcucurbitacin A	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants Cucumis melo Linn.	JAK
25-Deacetylcucurbitacin A is a Cucurbitane-Type triterpenoid and has the potential to be an anti-cancer agent and JAK/STAT3 signaling pathway inhibitor .

HY-N7452

Coumermycin A1	Structural Classification Microorganisms Antibiotics Source classification	JAK Bacterial Orthopoxvirus
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.

HY-N0678

Icaritin 1 Publications Verification Anhydroicaritin	Flavonols Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Berberidaceae Disease Research Fields Cancer	Autophagy Apoptosis
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[3.

HY-N0781

Linderalactone 1 Publications Verification	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Lauraceae Disease Research Fields Lindera aggregata (Sims) Kosterm. Cancer	Apoptosis
Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC₅₀ of 15 µM .

HY-N0697

Crocin 5+ Cited Publications Crocin I	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Lridaceae Plants Crocus sativus L. Functional Molecules Terpenoids Research of Health Products Diterpenoids Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite JAK Apoptosis
Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through *JAK* pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities .

HY-116035

Nimbolide 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Azadirachta indica A. Juss. Disease Research Fields Meliaceae Cancer	NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-N2409

Delphinidin chloride	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Plants Anthocyans Flavonoids other families Microorganisms Solanum melongena L. Phenols Polyphenols Solanaceae Disease Research Fields Cancer	Apoptosis EGFR JAK STAT
Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates *JAK/STAT3* and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC₅₀: 1.3 μM), shutting down downstream signaling cascades .

HY-N10623

5-epi-Arvestonate A	Structural Classification Natural Products Classification of Application Fields Plants Compositae Seriphidium transiliense Disease Research Fields Cancer	Tyrosinase
5-epi-Arvestonate A is a sesquiterpenoid isolated from the whole plants of Seriphidium transiliense. 5-epi-Arvestonate A promotes melanogenic production by activating the transcription of microphthalmia-associated transcription factor (MITF) and tyrosinase family genes. 5-epi-Arvestonate A inhibits the expression of IFN-γ-chemokine through the JAK/STAT signaling pathway in immortalized human keratinocyte (HaCaT) cells .

HY-16561

Resveratrol Maximum Cited Publications 77 Publications Verification trans-Resveratrol; SRT501	Structural Classification Classification of Application Fields Anti-aging Source classification Vitis vinifera cv. Zalema Plants Vitaceae Infection Microorganisms Functional Molecules Sunscreen Research of Health Products Phenols Polyphenols Cosmetic Research Inflammation/Immunology Disease Research Fields Cancer	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-16561R

Resveratrol (Standard) Maximum Cited Publications 77 Publications Verification trans-Resveratrol (Standard); SRT501 (Standard)	Infection Functional Molecules Classification of Application Fields Sunscreen Anti-aging Source classification Research of Health Products Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (Standard) is the analytical standard of Resveratrol. This product is intended for research and analytical applications. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

Cat. No.	Product Name	Chemical Structure

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-40354S

Tofacitinib-13C3

Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-40354AS

Tofacitinib-d3 citrate
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].

HY-W062703S

(Rac)-Ruxolitinib-d9

(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .

HY-W727879

Upadacitinib-15N,d2

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-131968

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-16561S1

Resveratrol-13C6

Resveratrol- ¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-16561S

Resveratrol-d4

Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks